Treatment Trials

8 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
      Description

      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

      Conditions
      Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid TumorUrothelial CarcinomaSolid Tumor, AdultBladder CancerNon-muscle-invasive Bladder CancerFGFR3 Gene MutationFGFR3 Gene AlterationAdvanced Solid TumorAdvanced Urothelial CarcinomaUrinary Tract CancerUrinary Tract TumorUrinary Tract Carcinoma
      Talk to us
      TERMINATED
      A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
      Description

      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

      Conditions
      Solid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma
      Talk to us
      RECRUITING
      Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
      Description

      Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

      Conditions
      Low-grade NMIBCFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationFGFR3 Gene Fusions
      Talk to us
      RECRUITING
      Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
      Description

      A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

      Conditions
      Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, AdultFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationAdvanced Solid TumorsFGFR4 Gene MutationFGFR4 Gene FusionsFGF19 Gene AmplificationFGF19 Gene OverexpressionFGFR3 Gene FusionsLocally Advanced Unresectable Hepatocellular Carcinoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
      Description

      This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.

      Conditions
      FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene TranslocationFGFR2 Gene AmplificationFGFR2 Gene MutationFGFR2 Gene TranslocationFGFR3 Gene AmplificationFGFR3 Gene MutationFGFR3 Gene TranslocationMetastatic Colorectal CarcinomaStage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Unresectable Colorectal Carcinoma
      Talk to us
      RECRUITING
      A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
      Description

      This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

      Conditions
      Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, AdultFGFR2 Gene Fusion/RearrangementFGFR2 Gene AmplificationFGFR2 Gene Short VariantsFGFR3 Gene Fusion/RearrangementFGFR3 Gene AmplificationFGFR3 Gene Short VariantsFGFR2 Genetic AlterationsFGFR3 Genetic AlterationsAdvanced Solid Tumors
      Talk to us
      COMPLETED
      Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
      Description

      This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR genetic aberrations, including iCCA with FGFR2 gene fusion (Part 2; Expanded Cohort, signal finding).

      Conditions
      Solid Tumor
      Talk to us
      COMPLETED
      Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
      Description

      This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

      Conditions
      CholangiocarcinomaFGFR2 FusionFGFR2 Gene MutationFGFR1 AlterationFGFR3 Alteration
      Talk to us